atezolizumab + cisplatin + gemcitabine

Atezolizumab + cisplatin + gemcitabine is a combination regimen used in oncology clinical trials, particularly for bladder cancer and urothelial carcinoma. It combines atezolizumab, a monoclonal antibody that inhibits the programmed death-ligand 1 (PD-L1), with cisplatin and gemcitabine, two cytotoxic chemotherapy agents. Atezolizumab acts as an immune checkpoint inhibitor, enhancing T-cell mediated antitumor responses by blocking PD-L1 interaction with PD-1 and B7.1. Cisplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis, while gemcitabine is a nucleoside analog inhibiting DNA synthesis through incorporation into DNA and inhibition of DNA polymerase. The combination is under investigation in phase II trials for neoadjuvant and metastatic settings for bladder cancer and urothelial carcinoma. The regimen is delivered via intravenous infusion in cycles, and studies show it may increase response rates and survival when compared to chemotherapy alone[1][2][3][4][5].

Brand names

atezolizumab + cisplatin + gemcitabine

Other names

atezolizumab + cisplatin + gemcitabine